AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets

US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.

The potential for dropped tablets will take center stage at an Oct. 12 meeting of the US FDA's Anesthetic And Analgesic Drug Products Advisory Committee, where panelists will weigh in on a series of questions the agency has about AcelRx Pharmaceuticals Inc.'s opioid Dsuvia (sufentanil sublingual tablet).

Designed for the management of moderate-to-severe acute pain severe enough to require an opioid analgesic and for which alternative treatments...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers